|
Akorn-Strides Gets FDA Approval for Flumazenil Injection
Akorn-Strides received an ANDA approval for Flumazenil Injection, packaged in 5-mL and 10-mL multiple-dose vials. Flumazenil Injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines. Recent data estimate an annual market size of approximately $14 million. Akorn-Strides is a joint venture that was formed in 2005 by Akorn and Strides Arcolab. |
Related Articles
Novo Nordisk Gearing Up to Double Down on Diabetes Drugs in 2013Possible FDA Approval of New Pain Drug Using Other Drug’s Data May Save Struggling NeurogesXDrug-Diagnostic Sponsors Must Educate Sites to Avoid Bias That Can Kill ApprovalPfizer Hopes Pipeline Will Overflow Soon, With Five Potential New Products This Year
|
Register Now
Archives